泼尼松龙在肾病患儿中的药代动力学。
Pharmacokinetics of prednisolone in children with nephrosis.
作者信息
Miller P F, Bowmer C J, Wheeldon J, Brocklebank J T
机构信息
Department of Paediatrics and Child Health, St James's University Hospital, Leeds.
出版信息
Arch Dis Child. 1990 Feb;65(2):196-200. doi: 10.1136/adc.65.2.196.
Abstract
The pharmacokinetics of prednisolone given intravenously were studied in 11 children with relapsed steroid responsive nephrotic syndrome, and four control subjects. The clearance of both total and unbound drug was decreased in these children and the unbound fraction of the drug in plasma was significantly correlated with the degree of hypoalbuminaemia. We conclude that changes in the clearance of prednisolone and altered protein binding might account for some of the variability in both therapeutic responses and the incidence of toxicity in patients treated with standard dosage regimens.
摘要
对11名复发的激素敏感型肾病综合征患儿及4名对照受试者进行了静脉注射泼尼松龙的药代动力学研究。这些患儿体内总药物和游离药物的清除率均降低，且血浆中药物的游离分数与低白蛋白血症程度显著相关。我们得出结论，泼尼松龙清除率的变化及蛋白结合改变可能是导致采用标准剂量方案治疗的患者治疗反应和毒性发生率出现差异的部分原因。
相似文献
1
Pharmacokinetics of prednisolone in children with nephrosis.泼尼松龙在肾病患儿中的药代动力学。
Arch Dis Child. 1990 Feb;65(2):196-200. doi: 10.1136/adc.65.2.196.
2
3
Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia.急性淋巴细胞白血病患儿中泼尼松龙的群体药代动力学
Cancer Chemother Pharmacol. 2003 Jun;51(6):465-73. doi: 10.1007/s00280-003-0602-3. Epub 2003 Apr 16.
4
Changes in the pharmacokinetics of plasma total and free prednisolone during daily and intermittent regimens.每日及间歇给药方案期间血浆总泼尼松龙和游离泼尼松龙药代动力学的变化。
J Clin Endocrinol Metab. 1990 Apr;70(4):957-64. doi: 10.1210/jcem-70-4-957.
5
Pharmacokinetics of prednisolone in children with the nephrotic syndrome.
Pediatr Nephrol. 1990 Sep;4(5):470-3. doi: 10.1007/BF00869822.
6
Saliva monitoring of prednisolone in children with first onset steroid-sensitive nephrotic syndrome: Is it possible?儿童初发激素敏感型肾病综合征唾液监测泼尼松龙：是否可行？
Br J Clin Pharmacol. 2024 Jul;90(7):1677-1687. doi: 10.1111/bcp.16066. Epub 2024 Apr 10.
7
Altered plasma protein-binding of prednisolone in patients with the nephrotic syndrome.肾病综合征患者泼尼松龙的血浆蛋白结合发生改变。
Am J Kidney Dis. 1984 Mar;3(5):339-48. doi: 10.1016/s0272-6386(84)80081-5.
8
Pharmacokinetics of prednisolone in children with acute lymphoblastic leukaemia.急性淋巴细胞白血病患儿中泼尼松龙的药代动力学
Cancer Chemother Pharmacol. 1989;23(6):392-4. doi: 10.1007/BF00435843.
9
10
Population Pharmacokinetics of Prednisolone in Relation to Clinical Outcome in Children With Nephrotic Syndrome.泼尼松龙在肾病综合征患儿中的群体药代动力学及其与临床结局的关系
Ther Drug Monit. 2016 Aug;38(4):534-45. doi: 10.1097/FTD.0000000000000308.
引用本文的文献
1
Prednisolone pharmacokinetics in dogs with protein-losing enteropathy.泼尼松龙在患有蛋白丢失性肠病犬中的药代动力学。
J Vet Intern Med. 2025 Jan-Feb;39(1):e17277. doi: 10.1111/jvim.17277.
2
Pharmacokinetics and Pharmacodynamics of Systemic Corticosteroids in Autoimmune and Inflammatory Diseases: A Review of Current Evidence.全身性皮质类固醇在自身免疫和炎症性疾病中的药代动力学和药效学：当前证据综述。
Clin Pharmacokinet. 2024 Sep;63(9):1251-1270. doi: 10.1007/s40262-024-01419-7. Epub 2024 Sep 12.
3
Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome.肾病综合征患者中泼尼松和泼尼松龙的药理学和药物遗传学。
Pediatr Nephrol. 2019 Mar;34(3):389-403. doi: 10.1007/s00467-018-3929-z. Epub 2018 Mar 16.
4
Glucocorticoid therapy regulates podocyte motility by inhibition of Rac1.糖皮质激素治疗通过抑制 Rac1 调节足细胞运动。
Sci Rep. 2017 Jul 27;7(1):6725. doi: 10.1038/s41598-017-06810-y.
5
Should we stop dosing steroids per body surface area for nephrotics?我们是否应该停止按照体表面积给肾病患者使用类固醇药物？
Pediatr Nephrol. 2016 Apr;31(4):519-22. doi: 10.1007/s00467-015-3286-0. Epub 2015 Dec 28.
6
Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome.特发性肾病综合征患儿麦考酚酸的群体药代动力学和贝叶斯估算。
Br J Clin Pharmacol. 2010 Apr;69(4):358-66. doi: 10.1111/j.1365-2125.2010.03615.x.
本文引用的文献
1
Inactivity in vivo of transcortin-bound cortisol.皮质素结合皮质醇在体内的无活性。
Science. 1962 Mar 23;135(3508):1062-3. doi: 10.1126/science.135.3508.1062.
2
Determination of prednisolone in plasma by high-performance liquid chromatography.
J Chromatogr. 1982 Nov 12;232(2):406-12. doi: 10.1016/s0378-4347(00)84181-x.
3
The binding of prednisolone in human serum and to recrystallized human albumin in vitro.泼尼松龙在人血清中的结合以及在体外与重结晶人白蛋白的结合。
Br J Clin Pharmacol. 1982 Nov;14(5):667-72. doi: 10.1111/j.1365-2125.1982.tb04954.x.
4
Binding of prednisolone to alpha 1-acid glycoprotein.泼尼松龙与α1-酸性糖蛋白的结合。
J Steroid Biochem. 1983 Feb;18(2):191-4. doi: 10.1016/0022-4731(83)90087-0.
5
Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephrotic syndrome during the active phase and in remission.泼尼松及其代谢产物泼尼松龙在肾病综合征患儿活动期和缓解期的药代动力学
Br J Clin Pharmacol. 1984 Apr;17(4):423-31. doi: 10.1111/j.1365-2125.1984.tb02367.x.
6
Risk of relapse in steroid-sensitive nephrotic syndrome: effect of stage of post-prednisone adrenocortical suppression.激素敏感型肾病综合征的复发风险：泼尼松后肾上腺皮质抑制阶段的影响
J Pediatr. 1983 Oct;103(4):553-7. doi: 10.1016/s0022-3476(83)80582-4.
7
Prednisone side-effects and serum-protein levels. A collaborative study.泼尼松的副作用与血清蛋白水平。一项合作研究。
Lancet. 1971 Oct 9;2(7728):778-80. doi: 10.1016/s0140-6736(71)92738-3.
8
Intermittent versus long-term tapering prednisolone for initial therapy in children with idiopathic nephrotic syndrome.
J Pediatr. 1988 Jan;112(1):122-6. doi: 10.1016/s0022-3476(88)80136-7.
9
Clinical pharmacokinetics in infants and children.婴幼儿临床药代动力学
Clin Pharmacokinet. 1976;1(1):2-24. doi: 10.2165/00003088-197601010-00002.
10
Plasma levels, half-life values, and correlation with physiologic assays for growth and immunity.血浆水平、半衰期值以及与生长和免疫生理检测的相关性。
J Pediatr. 1978 Aug;93(2):299-303. doi: 10.1016/s0022-3476(78)80529-0.
Zotero 插件